Search

Your search keyword '"McInerney, James"' showing total 10 results
Start Over Author "McInerney, James" Journal journal of neurosurgery
10 results on '"McInerney, James"'

1. Stereotactic radiosurgery in the management of non–small cell lung cancer brain metastases: a prospective study using the NeuroPoint Alliance Stereotactic Radiosurgery Registry

Author

Michalopoulos, Giorgos D., primary, Katsos, Konstantinos, additional, Grills, Inga S., additional, Warnick, Ronald E., additional, McInerney, James, additional, Attia, Albert, additional, Timmerman, Robert, additional, Chang, Eric, additional, Andrews, David W., additional, D’Ambrosio, Anthony L., additional, Cobb, William S., additional, Pouratian, Nader, additional, Spalding, Aaron C., additional, Walter, Kevin, additional, Jensen, Randy L., additional, Bydon, Mohamad, additional, Asher, Anthony L., additional, and Sheehan, Jason P., additional

Published
2024
Full Text
View/download PDF

2. Effect of cerebral arteriovenous malformation location on outcomes of repeat, single-fraction stereotactic radiosurgery: a matched-cohort analysis

Author

Mantziaris, Georgios, primary, Pikis, Stylianos, additional, Dumot, Chloe, additional, Dayawansa, Sam, additional, Liscak, Roman, additional, May, Jaromir, additional, Lee, Cheng-Chia, additional, Yang, Huai-Che, additional, Martínez Moreno, Nuria, additional, Martinez Álvarez, Roberto, additional, Lunsford, L. Dade, additional, Niranjan, Ajay, additional, Wei, Zhishuo, additional, Srinivasan, Priyanka, additional, Tang, Lilly W., additional, Nabeel, Ahmed M., additional, Reda, Wael A., additional, Tawadros, Sameh R., additional, Abdel Karim, Khaled, additional, El-Shehaby, Amr M. N., additional, Emad Eldin, Reem M., additional, Elazzazi, Ahmed Hesham, additional, Peker, Selcuk, additional, Samanci, Yavuz, additional, Padmanaban, Varun, additional, Jareczek, Francis J., additional, McInerney, James, additional, Cockroft, Kevin M., additional, Mathieu, David, additional, Aldakhil, Salman, additional, Alzate, Juan Diego, additional, Kondziolka, Douglas, additional, Tripathi, Manjul, additional, Palmer, Joshua D., additional, Upadhyay, Rituraj, additional, Lin, Michelle, additional, Zada, Gabriel, additional, Yu, Cheng, additional, Cifarelli, Christopher P., additional, Cifarelli, Daniel T., additional, Shaaban, Ahmed, additional, Xu, Zhiyuan, additional, and Sheehan, Jason P., additional

Published
2023
Full Text
View/download PDF

3. Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry

Author

Alvi, Mohammed Ali, primary, Asher, Anthony L., additional, Michalopoulos, Giorgos D., additional, Grills, Inga S., additional, Warnick, Ronald E., additional, McInerney, James, additional, Chiang, Veronica L., additional, Attia, Albert, additional, Timmerman, Robert, additional, Chang, Eric, additional, Kavanagh, Brian D., additional, Andrews, David W., additional, Walter, Kevin, additional, Bydon, Mohamad, additional, and Sheehan, Jason P., additional

Published
2022
Full Text
View/download PDF

4. Stereotactic radiosurgery for treatment of radiation-induced meningiomas: a multiinstitutional study

Author

Bunevicius, Adomas, primary, Suleiman, Mohand, additional, Patel, Samir, additional, Martínez Álvarez, Roberto, additional, Martinez Moreno, Nuria E., additional, Liscak, Roman, additional, Hanuska, Jaromir, additional, Langlois, Anne-Marie, additional, Mathieu, David, additional, Mau, Christine, additional, Caldwell, Catherine, additional, Tuanquin, Leonard C., additional, Zacharia, Brad E., additional, McInerney, James, additional, Lee, Cheng-Chia, additional, Yang, Huai-Che, additional, Peterson, Jennifer L., additional, Trifiletti, Daniel M., additional, Ogino, Akiyoshi, additional, Kano, Hideyuki, additional, Warnick, Ronald E., additional, Saylany, Anissa, additional, Buch, Love Y., additional, Lee, John Y. K., additional, Strickland, Ben A., additional, Zada, Gabriel, additional, Chang, Eric L., additional, Lunsford, L. Dade, additional, and Sheehan, Jason, additional

Published
2021
Full Text
View/download PDF

5. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study

Author

Hung, Yi-Chieh, primary, Lee, Cheng-Chia, additional, Yang, Huai-che, additional, Mohammed, Nasser, additional, Kearns, Kathryn N., additional, Nabeel, Ahmed M., additional, Abdel Karim, Khaled, additional, Emad Eldin, Reem M., additional, El-Shehaby, Amr M. N., additional, Reda, Wael A., additional, Tawadros, Sameh R., additional, Liscak, Roman, additional, Jezkova, Jana, additional, Lunsford, L. Dade, additional, Kano, Hideyuki, additional, Sisterson, Nathaniel D., additional, Martínez Álvarez, Roberto, additional, Martínez Moreno, Nuria E., additional, Kondziolka, Douglas, additional, Golfinos, John G., additional, Grills, Inga, additional, Thompson, Andrew, additional, Borghei-Razavi, Hamid, additional, Maiti, Tanmoy Kumar, additional, Barnett, Gene H., additional, McInerney, James, additional, Zacharia, Brad E., additional, Xu, Zhiyuan, additional, and Sheehan, Jason P., additional

Published
2020
Full Text
View/download PDF

6. Gamma Knife radiosurgery of saccular aneurysms in a rabbit model

Author

Meadowcroft, Mark D., primary, Cooper, Timothy K., additional, Rupprecht, Sebastian, additional, Wright, Thaddeus C., additional, Neely, Elizabeth E., additional, Ferenci, Michele, additional, Kang, Weimin, additional, Yang, Qing X., additional, Harbaugh, Robert E., additional, Connor, James R., additional, and McInerney, James, additional

Published
2018
Full Text
View/download PDF

9. Stereotactic radiosurgery in the management of non-small cell lung cancer brain metastases: a prospective study using the NeuroPoint Alliance Stereotactic Radiosurgery Registry.

Author

Michalopoulos GD, Katsos K, Grills IS, Warnick RE, McInerney J, Attia A, Timmerman R, Chang E, Andrews DW, D'Ambrosio AL, Cobb WS, Pouratian N, Spalding AC, Walter K, Jensen RL, Bydon M, Asher AL, and Sheehan JP

Subjects
Humans, Male, Female, Aged, Middle Aged, Prospective Studies, Aged, 80 and over, Treatment Outcome, Disease Progression, Adult, Karnofsky Performance Status, Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Non-Small-Cell Lung pathology, Radiosurgery, Brain Neoplasms secondary, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Lung Neoplasms pathology, Registries
Abstract

Objective: The literature on non-small cell lung cancer (NSCLC) brain metastases (BMs) managed using stereotactic radiosurgery (SRS) relies mainly on single-institution studies or randomized controlled trials (RCTs). There is a literature gap on clinical and radiological outcomes of SRS for NSCLC metastases in real-world practice. The objective of this study was to benchmark mortality and progression outcomes in patients undergoing SRS for NSCLC BMs and identify risk factors for these outcomes using a national quality registry., Methods: The SRS Registry of the NeuroPoint Alliance was used for this study. This registry included patients from 16 enrolling sites who underwent SRS from 2017 to 2022. Data are prospectively collected without a prespecified research purpose. The main outcomes of this analysis were overall survival (OS), out-of-field recurrence, local progression, and intracranial progression. All time-to-event investigations included Kaplan-Meier analyses and multivariable Cox regressions., Results: Two hundred sixty-four patients were identified, with a mean age of 66.7 years and a female proportion of 48.5%. Most patients (84.5%) had a Karnofsky Performance Status (KPS) score of 80-100, and the mean baseline EQ-5D score was 0.539 quality-adjusted life years. A single lesion was present in 53.4% of the patients, and 29.1% of patients had 3 or more lesions. The median OS was 28.1 months, and independent predictors of mortality included no control of primary tumor (hazard ratio [HR] 2.1), KPS of 80 (HR 2.4) or lower (HR 2.4), coronary artery disease (HR 2.8), and 5 or more lesions present at the time of SRS treatment (HR 2.3). The median out-of-field progression-free survival (PFS) was 24.8 months, and the median local PFS was unreached. Intralesional hemorrhage was an independent risk factor of local progression, with an HR of 6.0. The median intracranial PFS was 14.0 months and was predicted by the number of lesions at the time of SRS (3-4 lesions, HR 2.2; 5-14 lesions, HR 2.5)., Conclusions: In this real-world prospective study, the authors used a national quality registry and found favorable OS in patients with NSCLC BMs undergoing SRS compared with results from previously published RCTs. The intracranial PFS was mainly driven by the emergence of new lesions rather than local progression. A greater number of lesions at baseline was associated with out-of-field progression, while intralesional hemorrhage at baseline was associated with local progression.

Published
2023
Full Text
View/download PDF

10. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study.

Author

Hung YC, Lee CC, Yang HC, Mohammed N, Kearns KN, Nabeel AM, Abdel Karim K, Emad Eldin RM, El-Shehaby AMN, Reda WA, Tawadros SR, Liscak R, Jezkova J, Lunsford LD, Kano H, Sisterson ND, Martínez Álvarez R, Martínez Moreno NE, Kondziolka D, Golfinos JG, Grills I, Thompson A, Borghei-Razavi H, Maiti TK, Barnett GH, McInerney J, Zacharia BE, Xu Z, and Sheehan JP

Abstract

Objective: The most common functioning pituitary adenoma is prolactinoma. Patients with medically refractory or residual/recurrent tumors that are not amenable to resection can be treated with stereotactic radiosurgery (SRS). The aim of this multicenter study was to evaluate the role of SRS for treating prolactinomas., Methods: This retrospective study included prolactinomas treated with SRS between 1997 and 2016 at ten institutions. Patients' clinical and treatment parameters were investigated. Patients were considered to be in endocrine remission when they had a normal level of prolactin (PRL) without requiring dopamine agonist medications. Endocrine control was defined as endocrine remission or a controlled PRL level ≤ 30 ng/ml with dopamine agonist therapy. Other outcomes were evaluated including new-onset hormone deficiency, tumor recurrence, and new neurological complications., Results: The study cohort comprised 289 patients. The endocrine remission rates were 28%, 41%, and 54% at 3, 5, and 8 years after SRS, respectively. Following SRS, 25% of patients (72/289) had new hormone deficiency. Sixty-three percent of the patients (127/201) with available data attained endocrine control. Three percent of patients (9/269) had a new visual complication after SRS. Five percent of the patients (13/285) were recorded as having tumor progression. A pretreatment PRL level ≤ 270 ng/ml was a predictor of endocrine remission (p = 0.005, adjusted HR 0.487). An increasing margin dose resulted in better endocrine control after SRS (p = 0.033, adjusted OR 1.087)., Conclusions: In patients with medically refractory prolactinomas or a residual/recurrent prolactinoma, SRS affords remarkable therapeutic effects in endocrine remission, endocrine control, and tumor control. New-onset hypopituitarism is the most common adverse event.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results